Zeta Corporation is an ISO 13485:2016 and FDA registered biomedical company that manufactures and distributes IVD antibodies for Pathology/IHC. We provide the highest quality of antibodies to help pathologists diagnose human tumors and diseases. Zeta antibodies are carefully curated to produce reproducible results on formalin-fixed, paraffin-embedded (FFPE) sections manually or using commercially available automated equipment. Zeta utilizes its collective knowledge of over 75 years to validate and standardize every antibody individually for immunohistochemistry (IHC) application.
Zeta designs and develops tumor-specific biomarkers using cutting-edge technology to uniquely select the immunogens for our famed RAbMono™ (Rabbit Monoclonal) and MonoMAb™ (Monospecific monoclonal antibodies). Zeta’s MonoMAb™ and RAbMono™ Antibodies are produced through hybridoma and recombinant technologies.
MonoMAb™: The clones are first screened by ELISA and gel electrophoresis to determine their specificity. The selected antibodies are further screened by staining FFPE sections. Only those antibodies that worked on FFPE sections are selected for further protein array analysis to select the highly specific clones for IHC.
RAbMono™: Rabbit monoclonal primary antibodies are designed and developed by Zeta’s accomplished scientists and validated to perform with high sensitivity and specificity. It is our commitment to produce and release several primary antibodies for the routine and unique targets.
We are proud of our commitment to producing highly specific, target-validated, and characterized IVD primary biomarkers to aid pathologists in the differential diagnosis of various tumors.
Zeta Corporation sells the products directly in the US and distributes them to over 50 different countries globally through our trusted partners.
Zeta offers CE-IVD labeled products with European regulatory compliance and encourages distributors to register the products in the individual territories as needed. We also aid the clients and distributors with quality approvals through third-party QC bodies like the NordiQC, based in Denmark.
Provide the highest-quality diagnostic IVD antibodies assisting diagnosis, targeted therapy, and differential diagnosis of human diseases.
Be a global leader in target-validated and characterized IVD antibodies for Pathology and IHC with the RAbMono™ and MonoMAb™.